Genetic basis for adverse events after smallpox vaccination.

Identifying genetic factors associated with the development of adverse events might allow screening before vaccinia virus administration. Two independent clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in healthy, vaccinia virus-naive adult volunteers. Volunteers were assessed repeatedly for local and systemic adverse events (AEs) associated with the receipt of vaccine and underwent genotyping for 1,442 singlenucleotide polymorphisms (SNPs). In the first study, 36 SNPs in 26 genes were associated with systemic AEs (P <or= .05); these 26 genes were tested in the second study. In the final analysis, 3 SNPs were consistently associated with AEs in both studies. The presence of a nonsynonymous SNP in the methylenetetrahydrofolate reductase (MTHFR)gene was associated with the risk ofAEin both trials (odds ratio [OR], 2.3 [95% confidence interval {CI}, 1.1-5.2] [P = .04] and OR, 4.1 [95% CI, 1.4 -11.4] [P<.01]). Two SNPs in the interferon regulatory factor-1 (IRF1) gene were associated with the risk of AE in both sample sets (OR, 3.2 [95% CI, 1.1-9.8] [P = .03] andOR, 3.0 [95% CI, 1.1- 8.3] [P = .03]). Genetic polymorphisms in genes expressing an enzyme previously associated with adverse reactions to a variety of pharmacologic agents (MTHFR) and an immunological transcription factor (IRF1) were associated with AEs after smallpox vaccination in 2 independent study samples.

[1]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[2]  D. Koboldt,et al.  The immunogenetics of smallpox vaccination. , 2007, The Journal of infectious diseases.

[3]  G. Abecasis,et al.  A note on exact tests of Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[4]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[5]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[6]  S. Goodbourn,et al.  Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. , 2000, The Journal of general virology.

[7]  D. Bernstein,et al.  Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. , 2004, JAMA.

[8]  P. Kerr,et al.  Expression of rabbit IL-4 by recombinant myxoma viruses enhances virulence and overcomes genetic resistance to myxomatosis. , 2004, Virology.

[9]  David M. Reif,et al.  Cytokine expression patterns associated with systemic adverse events following smallpox immunization. , 2006, The Journal of infectious diseases.

[10]  James F. Jones,et al.  Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. , 2006, Immunity.

[11]  Nilanjan Chatterjee,et al.  Large-Scale Evaluation of Candidate Genes Identifies Associations between VEGF Polymorphisms and Bladder Cancer Risk , 2007, PLoS genetics.

[12]  M. Daly,et al.  High-resolution haplotype structure in the human genome , 2001, Nature Genetics.

[13]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[14]  B. LaFleur,et al.  Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. , 2003, JAMA.

[15]  Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men. , 2005, The Journal of nutrition.

[16]  E. Trabetti,et al.  The MTHFR 1298A>C Polymorphism and Genomic DNA Methylation in Human Lymphocytes , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  A. Kemper,et al.  Expected adverse events in a mass smallpox vaccination campaign. , 2002, Effective clinical practice : ECP.

[18]  D. Panagiotakos,et al.  An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. , 2005, International journal of cardiology.

[19]  T. Mosmann,et al.  The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones. , 1989, Journal of immunology.

[20]  J. Crowe,et al.  Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. , 2006, The Journal of infectious diseases.

[21]  Takashi Miyata,et al.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes , 1989, Cell.

[22]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[23]  A. Taniguchi,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. , 2002, Pharmacogenetics.

[24]  A. Alcamí,et al.  The Vaccinia Virus Soluble Alpha/Beta Interferon (IFN) Receptor Binds to the Cell Surface and Protects Cells from the Antiviral Effects of IFN , 2000, Journal of Virology.

[25]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[26]  N. Laird,et al.  Estimation and Tests of Haplotype-Environment Interaction when Linkage Phase Is Ambiguous , 2003, Human Heredity.

[27]  J. Crowe,et al.  Differential Regulation of Granzyme and Perforin in Effector and Memory T Cells following Smallpox Immunization1 , 2005, The Journal of Immunology.

[28]  J. McCluskey,et al.  Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate , 2006, Bone Marrow Transplantation.

[29]  M. Passo,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. , 1996, The Journal of pediatrics.

[30]  J. Crowe,et al.  Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. , 2004, The Journal of infectious diseases.

[31]  J. Butler,et al.  Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events. , 2004, The Journal of infectious diseases.

[32]  A. Alcamí,et al.  Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity , 1995, Cell.

[33]  Hugues Sicotte,et al.  SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes , 2005, Nucleic Acids Res..

[34]  R. Zinkernagel,et al.  Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors , 1995, Journal of virology.

[35]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[36]  A. Ramsay,et al.  Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox , 2001, Journal of Virology.

[37]  Dana C Crawford,et al.  Definition and clinical importance of haplotypes. , 2005, Annual review of medicine.

[38]  D. Schaid,et al.  Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics , 2006, Pharmacogenetics and genomics.